PADI1 and Its Co-Expressed Gene Signature Unveil Colorectal Cancer Prognosis and Immunotherapy Efficacy

Figure 9

The PCGs risk score predicted immunotherapeutic benefits. (a–d) The relative distribution of IPS was compared between PCGs scored high versus low groups in TCGA-CRC. (e) Distribution of immune dysfunction in high- and low-risk groups of PCGs. (f) Distribution of immune exclusion in high- and low-risk groups of PCGs. (g) Distribution of microsatellite instability (MSI) in high- and low-risk groups of PCGs. (h) Distribution of TIDE score in high- and low-risk groups of PCGs. , , .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)